Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna K K
Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
School of Natural Sciences, Griffith University, Brisbane, Queensland, Australia.
Oncogene. 2016 Feb 11;35(6):683-90. doi: 10.1038/onc.2015.128. Epub 2015 Apr 27.
CEP55 was initially identified as a pivotal component of abscission, the final stage of cytokinesis, serving to regulate the physical separation of two daughter cells. Over the past 10 years, several studies have illuminated additional roles for CEP55 including regulating the PI3K/AKT pathway and midbody fate. Concurrently, CEP55 has been studied in the context of cancers including those of the breast, lung, colon and liver. CEP55 overexpression has been found to significantly correlate with tumor stage, aggressiveness, metastasis and poor prognosis across multiple tumor types and therefore has been included as part of several prognostic 'gene signatures' for cancer. Here by discussing in depth the functions of CEP55 across different effector pathways, and also its roles as a biomarker and driver of tumorigenesis, we assemble an exhaustive review, thus commemorating a decade of research on CEP55.
CEP55最初被确定为胞质分裂最后阶段——脱落过程的关键组成部分，用于调节两个子细胞的物理分离。在过去十年中，多项研究揭示了CEP55的其他作用，包括调节PI3K/AKT通路和中体命运。同时，人们在包括乳腺癌、肺癌、结肠癌和肝癌在内的多种癌症背景下对CEP55进行了研究。研究发现，CEP55的过表达与多种肿瘤类型的肿瘤分期、侵袭性、转移和不良预后显著相关，因此已被纳入多种癌症的预后“基因特征”之中。在此，我们通过深入讨论CEP55在不同效应通路中的功能，以及它作为肿瘤发生的生物标志物和驱动因素的作用，进行了详尽的综述，以此纪念对CEP55长达十年的研究。
